CEACAM5 and colonic neoplasm: We, therefore, designed a pilot study to assess the immunogenicity and clinical activity of VRP-CEA(6D) in a group of patients with no evidence of disease but significant risk of recurrence, those with stage III colon cancer who had their primary disease resected and completed adjuvant chemotherapy.